Platinum-based treatments alone or in combination have generated interest in treating TNBC [37], due to lack of treatment options for this subtype of breast cancer, and their use has been supported by the strong association of TNBC tumors with germline mutations in the BRCA1 gene. This evidence concerns the gene BRCA1 and breast carcinoma.